Edwin M. Posadas, MD, FACP, presented “Current Advances of Liquid Biopsies in Prostate Cancer” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Posadas, Edwin M. “Current Advances of Liquid Biopsies in Prostate Cancer.” February 9, 2025. Accessed Mar 2025. https://grandroundsinurology.com/current-advances-of-liquid-biopsies-in-prostate-cancer/
Current Advances of Liquid Biopsies in Prostate Cancer – Summary
Edwin M. Posadas, MD, FACP, Cedars-Sinai Medical Center, Los Angeles, California, explores advancements in prostate cancer diagnostics and treatment. In this 15-minute presentation, Dr. Posadas emphasizes the evolving role of biomarkers and liquid biopsy technologies.
Dr. Posadas shares that liquid biopsies, particularly cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs), are emerging as valuable tools in tracking disease progression and treatment response. Data highlights cfDNA’s role in guiding treatment decisions. CTCs provide additional insights, with research demonstrating their ability to reflect tumor biology, including molecular changes in metastatic progression.
Dr. Posadas emphasizes integrating liquid biopsy data with molecular imaging to improve precision treatment strategies. Liquid biopsies offer cost-effective and accessible insights, and their adoption could complement existing imaging techniques, especially in detecting treatment resistance.
About the 35th International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.
The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.
ABOUT THE AUTHOR
Edwin M. Posadas, MD, FACP, is Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence (CURE) / Urologic Oncology Disease Research Group at Cedars-Sinai Medical Center. He is also an associate professor at Cedars-Sinai and a full professor at the University of California, Los Angeles. Dr. Posadas received his medical degree from Johns Hopkins and completed his residency at the University of Michigan before finishing a fellowship at the National Cancer Institute in Bethesda, Maryland.
Dr. Posadas’s clinical and research interests include the treatment of advanced prostate cancer and the biology of cancer metastasis. He is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. Hais current research interests focus on the most aggressive subtypes of prostate cancer that spread to organs such as the liver and lungs. Dr. Posadas’s laboratory has been studying the role of circulating tumor cells (CTCs) and immune cells (ICs) as biomarkers in prostate and other cancers using novel nanotechnology platforms. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care.
